Your browser is no longer supported. Please, upgrade your browser.
ESPR Esperion Therapeutics, Inc. daily Stock Chart
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.86 Insider Own0.10% Shs Outstand24.95M Perf Week6.37%
Market Cap1.94B Forward P/E- EPS next Y-5.82 Insider Trans-27.21% Shs Float22.38M Perf Month29.97%
Income-158.10M PEG- EPS next Q-1.79 Inst Own- Short Float11.73% Perf Quarter63.62%
Sales- P/S- EPS this Y-47.10% Inst Trans-3.41% Short Ratio4.77 Perf Half Y63.34%
Book/sh11.44 P/B6.81 EPS next Y20.40% ROA-66.00% Target Price77.50 Perf Year603.34%
Cash/sh8.15 P/C9.56 EPS next 5Y16.18% ROE-74.10% 52W Range10.71 - 78.59 Perf YTD18.36%
Dividend- P/FCF- EPS past 5Y38.00% ROI- 52W High-1.19% Beta2.70
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low625.02% ATR3.34
Employees44 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)71.97 Volatility5.10% 5.09%
OptionableYes Debt/Eq0.01 EPS Q/Q-141.00% Profit Margin- Rel Volume1.19 Prev Close77.93
ShortableYes LT Debt/Eq0.00 EarningsFeb 21 AMC Payout- Avg Volume550.18K Price77.65
Recom1.80 SMA2013.04% SMA5027.94% SMA20061.26% Volume134,329 Change-0.36%
Jan-22-18Downgrade Citigroup Buy → Neutral
Jan-18-18Initiated Credit Suisse Outperform $103
Jan-17-18Reiterated UBS Buy $62 → $88
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Dec-14-17Upgrade Needham Buy → Strong Buy $72 → $81
Dec-06-17Reiterated Chardan Capital Markets Neutral $20 → $75
Aug-29-17Initiated Northland Capital Outperform $72
Aug-11-17Resumed BofA/Merrill Neutral
Aug-09-17Upgrade Jefferies Hold → Buy
Jul-11-17Initiated Jefferies Hold
Jun-27-17Reiterated Stifel Buy $45 → $60
Jun-23-17Initiated Deutsche Bank Buy $48
Mar-30-17Upgrade UBS Neutral → Buy $23 → $52
Mar-20-17Upgrade Credit Suisse Underperform → Neutral
Feb-28-17Upgrade Citigroup Neutral → Buy
Feb-23-17Reiterated RBC Capital Mkts Sector Perform $20 → $30
Nov-14-16Downgrade Citigroup Buy → Neutral
Jul-05-16Downgrade WallachBeth Buy → Hold $35
Jun-30-16Reiterated Needham Buy $77 → $25
Jun-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $30 → $15
Jan-22-18 09:58AM  Citi Downgrades Esperion As Hope Of Acquisition Dwindles Benzinga
Jan-14-18 09:00AM  5 Biotech Stocks That Could Be Bought Out in 2018 Motley Fool
Jan-08-18 06:03AM  The 10 Best Stocks of 2017 Motley Fool
Jan-06-18 10:31AM  Why Esperion Therapeutics Shares Skyrocketed 425.9% in 2017 Motley Fool
Jan-03-18 04:30PM  Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-14-17 04:30PM  Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors GlobeNewswire
Dec-04-17 09:32AM  3 Stocks That Quadrupled Motley Fool -5.06%
Dec-01-17 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-17 03:43PM  Esperion Therapeutics, Inc. Fundamental Analysis : November 30, 2017 Capital Cube
Nov-13-17 04:30PM  Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference GlobeNewswire
07:30AM  Earnings Review and Free Research Report: Vertexs Revenue Soared 40%; Adjusted EPS Rocketed 212% ACCESSWIRE
Nov-09-17 04:30PM  Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference GlobeNewswire
Nov-07-17 08:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 04:30PM  Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill GlobeNewswire
Oct-10-17 08:30AM  Esperion to Host Analyst and Investor Day Event on October 17 GlobeNewswire
Oct-02-17 04:30PM  Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid GlobeNewswire
Aug-28-17 07:12PM  Cramer Remix: Here's how North Korea's missile could impa... CNBC Videos
06:59PM  Cramer Remix: Here's how North Korea's missile could impact the stock market CNBC
Aug-18-17 07:17AM  These Stocks Have Quadrupled Since Last Year Motley Fool
Aug-14-17 04:30PM  Edited Transcript of ESPR earnings conference call or presentation 8-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
11:49AM  The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant Zacks
Aug-11-17 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:05AM  Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure Zacks
Aug-09-17 09:20PM  Esperion Prices Public Offering of Common Stock GlobeNewswire
08:10AM  Today's Research Reports on Stocks to Watch: Esperion Therapeutics and Valeant Pharmaceuticals ACCESSWIRE
Aug-08-17 11:56PM  Esperion Therapeutics reports 2Q loss Associated Press +15.41%
04:32PM  Esperion Announces Proposed Public Offering of Common Stock GlobeNewswire
12:46PM  Here's What's Pushing Up Esperion Therapeutics Inc. Today Motley Fool
08:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results GlobeNewswire
07:30AM  Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin GlobeNewswire
05:20AM  Investor Network: Esperion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 08:59AM  Should You Buy Esperion Therapeutics (ESPR) Ahead of Earnings? Zacks
Aug-02-17 04:30PM  Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results GlobeNewswire
Aug-01-17 06:29PM  What to Expect from Epizyme (EPZM) This Earnings Season? Zacks
11:56AM  What's in the Cards for Endo (ENDP) this Earnings Season? Zacks
Jul-26-17 04:30PM  Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor GlobeNewswire
03:59PM  The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug Motley Fool
Jul-21-17 02:42PM  3 Been-There-Done-That Biotech CEOs Who Are Doing it Again Motley Fool
Jul-20-17 09:02PM  3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now? Motley Fool +5.63%
Jul-17-17 07:00AM  3 Small Biotech Stocks Being Run by Proven Winners Motley Fool
Jun-30-17 05:46PM  3 Stocks That Turned $7,000 Into As Much As $37,000 So Far in 2017 Motley Fool
Jun-29-17 08:20AM  Esperion Therapeutics (ESPR) Looks Good: Stock Gains 10.4% Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Heat Biologics Inc. and Esperion Therapeutics Accesswire
Jun-28-17 06:14PM  Here's Why Shares of Esperion Therapeutics (ESPR) Popped Today Zacks +10.38%
04:17PM  Esperion Breaks Out On Cholesterol Tie-Up With Dow's Merck Investor's Business Daily
10:30AM  Esperion's Combo Cholesterol Candidate Enters Phase III Zacks
Jun-26-17 04:05PM  Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe GlobeNewswire
Jun-23-17 09:54AM  Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold Benzinga
Jun-22-17 03:42PM  If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy Motley Fool
12:19PM  3 Hot Plays in the Resurgent Biotech Sector Investopedia
Jun-21-17 04:33PM  Biotechs Surge As Generalists Return Amid Subsiding Trump Woes Investor's Business Daily +19.21%
Jun-14-17 04:30PM  Esperion to Present at the JMP Securities 2017 Life Sciences Conference GlobeNewswire
Jun-09-17 01:19PM  Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct
May-31-17 04:30PM  Esperion to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-22-17 08:05AM  Esperion Provides Update on Common Stock Trading Activity GlobeNewswire
May-19-17 04:30PM  Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference GlobeNewswire -8.14%
May-18-17 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-12-17 04:30PM  Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference GlobeNewswire
May-08-17 08:00AM  Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics Accesswire
May-06-17 08:01AM  Why Esperion Therapeutics Shares Were Flat In April Motley Fool
May-05-17 05:02AM  Esperion Therapeutics reports 1Q loss Associated Press -5.22%
May-04-17 04:05PM  Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results GlobeNewswire
May-01-17 02:32PM  3 Best Biotech Stocks During Trump's First 100 Days Motley Fool
Apr-28-17 09:21AM  Biotech And Pharma Industry And Stock News Investor's Business Daily
Apr-26-17 05:28PM  Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Investor's Business Daily
Apr-11-17 07:02AM  3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich Motley Fool
Apr-10-17 06:51PM  Cramer's lightning round: I may be alone on this, but this e-commerce play is going higher CNBC +7.57%
Apr-07-17 09:30AM  The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics Zacks
Apr-06-17 09:32AM  3 of the Best & Worst Performing Drug Stocks of Q1 Zacks
Mar-31-17 08:21AM  Could Pfizer Buy Esperion Therapeutics? Motley Fool
Mar-30-17 04:20PM  The 3 Best Cholesterol Drug Stocks to Buy in 2017 Motley Fool
04:08PM  Which Biotechs Are Buyable As Sector Recovers In 2017? Investor's Business Daily
10:33AM  5 Top Performing Stocks of the Best ETF of Q1 Zacks
09:03AM  Esperion Therapeutics upgraded by UBS
Mar-28-17 04:30PM  Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference GlobeNewswire -6.82%
Mar-24-17 12:00PM  3 Hot Biotech Stocks Now Motley Fool
Mar-21-17 10:10AM  Company News for March 21, 2017 Zacks -5.26%
09:32AM  Biotech Premarket Movers: Esperion, Minerva and BioCryst
09:30AM  The Difference Between Spectacular News and No News Accesswire
Mar-20-17 08:08PM  Esperion Therapeutics Inc (ESPR): Get It While Its Cheap Insider Monkey +74.14%
06:21PM  After-hours buzz: ESPR, NKTR, MMSI & more at CNBC
05:02PM  Here's What Pushed Esperion Therapeutics Inc Stock Higher Today at Motley Fool
04:09PM  Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
02:03PM  How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
12:42PM  Nektar, AMD, Esperion, and More: Heres Why These Five Stocks Are Surging at Insider Monkey
12:05PM  Esperion Gets FDA Nod for Cholesterol Drug Program at Investopedia
11:01AM  Esperion Therapeutics stock surges 52% after it says the FDA gave its drug program positive feedback at MarketWatch
10:55AM  Mondays Top Biopharma Movers
09:35AM  Biotech Premarket Movers: CytomX, Aevi, Esperion
07:46AM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:32AM  Esperion Therapeutics Sees Clear FDA Path For Its Heart Drug at Forbes
07:30AM  Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid GlobeNewswire
Mar-17-17 04:50PM  Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing -20.17%
04:28PM  Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble
02:56PM  Amgen, Esperion, AmTrust Financial and More: What is Going On With These Falling Stocks? at Insider Monkey
01:18PM  Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today at Motley Fool
11:03AM  [video]AveXis, Esperion and Amgen Among Biotech Movers
Mar-14-17 04:06PM  Amgen Could Boost Rivals On Positive Heart-Disease Study: Analyst
Mar-09-17 08:15AM  Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6%
Mar-08-17 04:26PM  Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High +8.59%
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JANNEY DANIELDirectorJan 18Option Exercise6.9971,237497,947631,204Jan 22 08:49 PM
Bartram RichardChief Financial OfficerJan 02Option Exercise3.7017,89266,20019,092Jan 03 06:01 PM
GOLDSTEIN DOV A MDDirectorDec 18Option Exercise3.7021,47179,44321,518Dec 20 05:53 PM
VITULLO NICOLEDirectorDec 06Sale53.859,326502,20525,927Dec 08 04:14 PM
OMENN GILBERT SDirectorMar 21Buy42.261,00042,2601,000Mar 22 08:02 AM
JANNEY DANIELDirectorMar 21Sale45.80350,00016,029,2631,359,967Mar 23 04:45 PM
GOLDSTEIN DOV A MDDirectorMar 21Sale43.48487,35821,190,3261,149,767Mar 23 04:37 PM